Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies
Executive Summary
Apotex argues that biosimilar studies in healthy volunteers are not sufficient to show clinically meaningful differences with the reference product; Coherus says it believes its application is scientifically sound.
You may also be interested in...
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Despite facing one-year delay, Coherus is buoyed by FDA’s apparent support for its decision not to conduct clinical study in cancer patients; agency requests company develop more sensitive immunogenicity assay and reanalyze subset of samples from study conducted in healthy subjects.
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Despite facing one-year delay, Coherus is buoyed by FDA’s apparent support for its decision not to conduct clinical study in cancer patients; agency requests company develop more sensitive immunogenicity assay and reanalyze subset of samples from study conducted in healthy subjects.